• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

危重症新生儿和儿童脓毒症中的脂多糖结合蛋白、脂多糖及可溶性CD14

Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children.

作者信息

Pavcnik-Arnol Maja, Hojker Sergej, Derganc Metka

机构信息

University Medical Center Ljubljana, Department of Pediatric Surgery and Intensive Care, Zaloska 7, 1525 Ljubljana, Slovenia.

出版信息

Intensive Care Med. 2007 Jun;33(6):1025-32. doi: 10.1007/s00134-007-0626-y. Epub 2007 Apr 5.

DOI:10.1007/s00134-007-0626-y
PMID:17410342
Abstract

OBJECTIVE

To compare the diagnostic accuracy of lipopolysaccharide-binding protein (LBP) for sepsis in critically ill neonates and children with the two markers participating in the same inflammatory pathway, lipopolysaccharide and soluble CD14.

DESIGN AND SETTING

Prospective, observational study in a multidisciplinary neonatal and pediatric intensive care unit.

PATIENTS

47 critically ill neonates and 49 critically ill children with systemic inflammatory response syndrome (SIRS) and suspected sepsis, classified into two groups: those with and those without sepsis.

INTERVENTIONS

Serum LBP, lipopolysaccharide, soluble CD14, C-reactive protein, and procalcitonin were measured on 2 consecutive days. The area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and predictive values were evaluated.

RESULTS

AUC for LBP on the first day of suspected infection was 0.97 in neonates aged under 48 h, 0.93 in neonates over 48 h and 0.82 in children. AUCs for lipopolysaccharide and soluble CD14 were 0.77 and 0.74 in neonates under 48 h, 0.53 and 0.76 in neonates over 48 h, and 0.72 and 0.53 in children. AUCs for procalcitonin and C-reactive protein were 0.65 and 0.89 in neonates under 48 h, 0.65 and 0.91 in neonates over 48 h, and 0.76 and 0.69 in children.

CONCLUSIONS

In critically ill neonates and children LBP concentration on the first day of suspected sepsis is a better marker of sepsis than lipopolysaccharide, soluble CD14, procalcitonin, and in neonates younger than 48 h and children, also a better marker than C-reactive protein. Lipopolysaccharide and soluble CD14 are not suitable markers for the differentiation of infectious and noninfectious SIRS.

摘要

目的

比较脂多糖结合蛋白(LBP)与参与同一炎症途径的两种标志物脂多糖和可溶性CD14对危重新生儿和儿童败血症的诊断准确性。

设计与地点

在多学科新生儿和儿科重症监护病房进行的前瞻性观察研究。

患者

47例危重新生儿和49例患有全身炎症反应综合征(SIRS)且疑似败血症的危重症儿童,分为两组:有败血症组和无败血症组。

干预措施

连续两天检测血清LBP、脂多糖、可溶性CD14、C反应蛋白和降钙素原。评估受试者工作特征曲线(AUC)下面积、敏感性、特异性和预测值。

结果

疑似感染第一天LBP的AUC在48小时以下的新生儿中为0.97,48小时以上的新生儿中为0.93,儿童中为0.82。脂多糖和可溶性CD14的AUC在48小时以下的新生儿中分别为0.77和0.74,48小时以上的新生儿中分别为0.53和0.76,儿童中分别为0.72和0.53。降钙素原和C反应蛋白的AUC在48小时以下的新生儿中分别为0.65和0.89,48小时以上的新生儿中分别为0.65和0.91,儿童中分别为0.76和0.69。

结论

在危重新生儿和儿童中,疑似败血症第一天的LBP浓度比脂多糖、可溶性CD14、降钙素原是更好的败血症标志物,在48小时以下的新生儿和儿童中,也比C反应蛋白是更好的标志物。脂多糖和可溶性CD14不是区分感染性和非感染性SIRS的合适标志物。

相似文献

1
Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children.危重症新生儿和儿童脓毒症中的脂多糖结合蛋白、脂多糖及可溶性CD14
Intensive Care Med. 2007 Jun;33(6):1025-32. doi: 10.1007/s00134-007-0626-y. Epub 2007 Apr 5.
2
Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein.疑似感染的危重新生儿和儿童体内的脂多糖结合蛋白:与降钙素原、白细胞介素-6和C反应蛋白的比较
Intensive Care Med. 2004 Jul;30(7):1454-60. doi: 10.1007/s00134-004-2307-4. Epub 2004 May 4.
3
Neutrophil and monocyte CD64 indexes, lipopolysaccharide-binding protein, procalcitonin and C-reactive protein in sepsis of critically ill neonates and children.中性粒细胞和单核细胞 CD64 指数、脂多糖结合蛋白、降钙素原和 C 反应蛋白在危重新生儿和儿童脓毒症中的应用。
Intensive Care Med. 2009 Nov;35(11):1950-8. doi: 10.1007/s00134-009-1637-7.
4
Soluble CD14 subtype (sCD14-ST) presepsin in premature and full term critically ill newborns with sepsis and SIRS.患有脓毒症和全身炎症反应综合征的早产及足月危重新生儿中的可溶性CD14亚型(sCD14-ST)前降钙素。
Clin Chim Acta. 2015 Dec 7;451(Pt A):65-70. doi: 10.1016/j.cca.2015.07.025. Epub 2015 Jul 29.
5
Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients.脂多糖结合蛋白(一种急性期蛋白)在重症患者监测中的意义。
Crit Care. 2003 Dec;7(6):R154-9. doi: 10.1186/cc2386. Epub 2003 Oct 1.
6
Sepsis biomarkers in neutropaenic systemic inflammatory response syndrome patients on standard care wards.标准护理病房中中性粒细胞减少性全身炎症反应综合征患者的脓毒症生物标志物
Eur J Clin Invest. 2015 Aug;45(8):815-23. doi: 10.1111/eci.12476.
7
Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome.降钙素原和C反应蛋白作为危重症儿童全身炎症反应综合征发作时细菌感染的标志物。
Pediatr Crit Care Med. 2008 Jul;9(4):407-13. doi: 10.1097/PCC.0b013e31817285a6.
8
Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis?外科重症监护病房中的脂多糖结合蛋白:脓毒症的标志物?
Crit Care Med. 2008 Jul;36(7):2014-22. doi: 10.1097/CCM.0b013e31817b86e3.
9
High-mobility group box-1 protein, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in children with community acquired infections and bacteraemia: a prospective study.高迁移率族蛋白 B1 、脂多糖结合蛋白、白细胞介素 6 和 C 反应蛋白在儿童社区获得性感染和菌血症中的作用:一项前瞻性研究。
BMC Infect Dis. 2010 Feb 16;10:28. doi: 10.1186/1471-2334-10-28.
10
Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children.降钙素原和C反应蛋白作为危重症儿童全身炎症反应综合征严重程度的标志物。
Intensive Care Med. 2007 Mar;33(3):477-84. doi: 10.1007/s00134-006-0509-7. Epub 2007 Jan 27.

引用本文的文献

1
Current Status of Antibiotic Stewardship and the Role of Biomarkers in Antibiotic Stewardship Programs.抗生素管理的现状及生物标志物在抗生素管理计划中的作用
Infect Chemother. 2022 Dec;54(4):674-698. doi: 10.3947/ic.2022.0172.
2
Association between elevation of plasma biomarkers and monocyte dysfunction and their combination in predicting sepsis: An observational single-centre cohort study.血浆生物标志物升高与单核细胞功能障碍及其联合预测脓毒症的相关性:一项观察性单中心队列研究。
Innate Immun. 2020 Aug;26(6):514-527. doi: 10.1177/1753425920926602. Epub 2020 May 26.
3
The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis.

本文引用的文献

1
Procalcitonin is not sufficiently reliable to be the sole marker of neonatal sepsis of nosocomial origin.降钙素原作为医院获得性新生儿败血症的唯一标志物,其可靠性不足。
BMC Pediatr. 2006 May 18;6:16. doi: 10.1186/1471-2431-6-16.
2
Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study.降钙素原、脂多糖结合蛋白、白细胞介素-6和C反应蛋白在社区获得性感染和脓毒症中的研究:一项前瞻性研究
Crit Care. 2006;10(2):R53. doi: 10.1186/cc4866.
3
Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram.
降钙素原在新生儿败血症中的诊断准确性:一项荟萃分析。
Eur J Pediatr. 2018 May;177(5):625-632. doi: 10.1007/s00431-018-3114-1. Epub 2018 Feb 23.
4
Diagnostics for neonatal sepsis: current approaches and future directions.新生儿败血症的诊断:当前方法和未来方向。
Pediatr Res. 2017 Oct;82(4):574-583. doi: 10.1038/pr.2017.134. Epub 2017 Jun 28.
5
Serum Procalcitonin as a Useful Serologic Marker for Differential Diagnosis between Acute Gouty Attack and Bacterial Infection.血清降钙素原作为急性痛风发作与细菌感染鉴别诊断的有用血清学标志物。
Yonsei Med J. 2016 Sep;57(5):1139-44. doi: 10.3349/ymj.2016.57.5.1139.
6
Early-Onset Neonatal Sepsis: Still Room for Improvement in Procalcitonin Diagnostic Accuracy Studies.早发型新生儿败血症:降钙素原诊断准确性研究仍有改进空间。
Medicine (Baltimore). 2015 Jul;94(30):e1230. doi: 10.1097/MD.0000000000001230.
7
Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein.脂多糖结合蛋白对发热性中性粒细胞减少症患儿菌血症/临床脓毒症的诊断准确性:与白细胞介素-6、降钙素原和 C 反应蛋白的比较。
Support Care Cancer. 2014 Jan;22(1):269-77. doi: 10.1007/s00520-013-1978-1. Epub 2013 Sep 21.
8
Lipopolysaccharide-binding protein: a potential marker of febrile urinary tract infection in childhood.脂多糖结合蛋白:儿童发热性尿路感染的潜在标志物。
Pediatr Nephrol. 2013 Jul;28(7):1091-7. doi: 10.1007/s00467-013-2432-9. Epub 2013 Mar 6.
9
Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities.可溶性 CD14 亚型(sCD14-ST)对死后诊断脓毒症相关死亡的诊断价值。
Int J Legal Med. 2013 Jul;127(4):799-808. doi: 10.1007/s00414-012-0804-5. Epub 2012 Dec 22.
10
Emerging biomarkers for the diagnosis of severe neonatal infections applicable to low resource settings.用于诊断资源匮乏环境下严重新生儿感染的新兴生物标志物。
J Glob Health. 2011 Dec;1(2):210-23.
出生后最初几天早产儿的降钙素原:引入与年龄相关的列线图。
Arch Dis Child Fetal Neonatal Ed. 2006 Jul;91(4):F283-6. doi: 10.1136/adc.2005.085449. Epub 2006 Mar 17.
4
The role of lipopolysaccharide-binding protein in modulating the innate immune response.脂多糖结合蛋白在调节先天性免疫反应中的作用。
Microbes Infect. 2006 Mar;8(3):946-52. doi: 10.1016/j.micinf.2005.10.006. Epub 2006 Jan 13.
5
Lipopolysaccharide-binding protein in noninfected neonates and those with suspected early-onset bacterial infection.未感染新生儿及疑似早发性细菌感染新生儿体内的脂多糖结合蛋白
J Perinatol. 2006 Feb;26(2):115-9. doi: 10.1038/sj.jp.7211422.
6
Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome.降钙素原确实能够区分脓毒症和全身炎症反应综合征。
Arch Dis Child. 2006 Feb;91(2):117-20. doi: 10.1136/adc.2005.077446. Epub 2005 Dec 2.
7
Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis.评估一种新发现的可溶性CD14亚型作为脓毒症标志物的作用。
J Infect Chemother. 2005 Oct;11(5):234-8. doi: 10.1007/s10156-005-0400-4.
8
Scope and epidemiology of pediatric sepsis.儿童脓毒症的范围及流行病学
Pediatr Crit Care Med. 2005 May;6(3 Suppl):S3-5. doi: 10.1097/01.PCC.0000161289.22464.C3.
9
The dynamics of LPS recognition: complex orchestration of multiple receptors.脂多糖识别的动力学:多种受体的复杂协调作用
J Endotoxin Res. 2005;11(1):5-11. doi: 10.1179/096805105225006641.
10
International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.国际儿童脓毒症共识会议:儿童脓毒症及器官功能障碍的定义
Pediatr Crit Care Med. 2005 Jan;6(1):2-8. doi: 10.1097/01.PCC.0000149131.72248.E6.